Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

245.90USD
11:13pm IST
Change (% chg)

$1.64 (+0.67%)
Prev Close
$244.26
Open
$244.97
Day's High
$246.77
Day's Low
$243.60
Volume
211,848
Avg. Vol
491,846
52-wk High
$374.94
52-wk Low
$243.60

Select another date:

Wed, Oct 21 2020

Photo

Biogen readies for U.S. launch of Alzheimer's drug ahead of FDA meeting

Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

UPDATE 3-Biogen readies for U.S. launch of Alzheimer's drug ahead of FDA meeting

Oct 21 Biogen Inc said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

BRIEF-Biogen Says U.S. FDA Decision On Aducanumab Would Influnce Other Regulators: Conf. Call

* BIOGEN INC CEO SAYS UPCOMING FDA PANEL MEETING FOR ADUCANUMAB IS CO'S HIGHEST PRIORITY: CONF. CALL

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease

U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig's disease.

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease

Oct 6 U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig's disease.

Alzheimer's drug from Biogen to get speedy U.S. review

The U.S. Food and Drug Administration will conduct an expedited review of an experimental Alzheimer's drug from Biogen Inc and Japan's Eisai Co Ltd, the companies said on Friday, the first application in 17 years to be reviewed by the agency for a treatment of the mind-robbing disease.

REFILE-UPDATE 3-Alzheimer's drug from Biogen to get speedy U.S. review

Aug 7 The U.S. Food and Drug Administration will conduct an expedited review of an experimental Alzheimer's drug from Biogen Inc and Japan's Eisai Co Ltd, the companies said on Friday, the first application in 17 years to be reviewed by the agency for a treatment of the mind-robbing disease.

U.S. FDA accepts Biogen's marketing application for Alzheimer's drug

Aug 7 Biogen Inc and Japan's Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer's disease treatment aducanumab.

Biogen lifts full-year profit forecast as Tecfidera boosts quarter

Biogen Inc raised its 2020 earnings forecast on Wednesday after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates.

UPDATE 3-Biogen lifts full-year profit forecast as Tecfidera boosts quarter

July 22 Biogen Inc raised its 2020 earnings forecast on Wednesday after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates.

Select another date: